Company intelligence / Profile preview

Neuroplast

Ownership: Private
Development stage: Phase 2

Overview

Neuroplast has developed a first-in-kind autologous stem cell therapy aimed at treating neurodegenerative diseases. Its lead program targets traumatic spinal cord injury and entered Phase II clinical trials in early 2022. The company positions itself as a global partner in neuro-regenerative medicine with the goal of providing effective treatments where none currently exist.

Therapeutic areas: Neurology
Modalities: Autologous stem cell therapy
Industry: Biotech

Drug pipeline

1 asset

Neuro-Cells

Beyond the preview

Go deeper on Neuroplast.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuroplast.